Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Blood

Retrieve available abstracts of 399 articles:
HTML format
Text format



Single Articles


    April 2017
  1. KRUTH K, Fang M, Shelton DN, Abu-Halawa O, et al
    Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.
    Blood. 2017 Apr 19. pii: blood-2017-02-766204. doi: 10.1182/blood-2017-02-766204
    PubMed     Text format     Abstract available


  2. DING W, LaPlant BR, Call TG, Parikh SA, et al
    Pembrolizumab in patients with chronic lymphocytic leukemia with Richter's transformation and relapsed CLL.
    Blood. 2017 Apr 19. pii: blood-2017-02-765685. doi: 10.1182/blood-2017-02-765685
    PubMed     Text format     Abstract available


  3. VUJKOVIC M, Attiyeh EF, Ries RE, Goodman EK, et al
    Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
    Blood. 2017 Apr 14. pii: blood-2017-03-772384. doi: 10.1182/blood-2017-03-772384
    PubMed     Text format     Abstract available


  4. GARDNER RA, Finney O, Annesley C, Brakke H, et al
    Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults.
    Blood. 2017 Apr 13. pii: blood-2017-02-769208. doi: 10.1182/blood-2017-02-769208
    PubMed     Text format     Abstract available


  5. HU S, Qian M, Zhang H, Guo Y, et al
    Whole-genome non-coding sequence analysis in T-cell acute lymphoblastic leukemia identifies oncogene enhancer mutations.
    Blood. 2017 Apr 13. pii: blood-2017-03-771162. doi: 10.1182/blood-2017-03-771162
    PubMed     Text format    



  6. Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017;129(9):1134-1142.
    Blood. 2017;129:2204.
    PubMed     Text format    


  7. UFFMANN M, Rasche M, Zimmermann M, von Neuhoff C, et al
    Therapy reduction in patients with Down Syndrome Myeloid Leukemia: The international ML-DS 2006 trial.
    Blood. 2017 Apr 11. pii: blood-2017-01-765057. doi: 10.1182/blood-2017-01-765057
    PubMed     Text format     Abstract available


  8. BELDERBOS ME, Koster T, Ausema B, Jacobs S, et al
    Clonal selection and asymmetric distribution of human leukemia in murine xenografts revealed by cellular barcoding.
    Blood. 2017 Apr 10. pii: blood-2016-12-758250. doi: 10.1182/blood-2016-12-758250
    PubMed     Text format     Abstract available


  9. TAUB JW, Berman JN, Hitzler JK, Sorrell AD, et al
    Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
    Blood. 2017 Apr 7. pii: blood-2017-01-764324. doi: 10.1182/blood-2017-01-764324.
    PubMed     Text format     Abstract available


    March 2017
  10. GARZON R, Savona M, Baz R, Andreeff M, et al
    A phase I clinical trial of single-agent selinexor in acute myeloid leukemia.
    Blood. 2017 Mar 23. pii: blood-2016-11-750158. doi: 10.1182/blood-2016-11-750158
    PubMed     Text format     Abstract available


  11. FISCHER K, Al-Sawaf O, Fink AM, Dixon M, et al
    Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
    Blood. 2017 Mar 21. pii: blood-2017-01-761973. doi: 10.1182/blood-2017-01-761973
    PubMed     Text format    


  12. CHENG CK, Wang AZ, Wong TH, Wan TS, et al
    FNDC3B is another novel partner fused to RARA in the t(3;17)(q26;q21) variant of acute promyelocytic leukemia.
    Blood. 2017 Mar 17. pii: blood-2017-02-767707. doi: 10.1182/blood-2017-02-767707
    PubMed     Text format    


  13. LOGHAVI S, Khoury JD
    Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence.
    Blood. 2017;129:1563.
    PubMed     Text format    


  14. HEIN N, Cameron DP, Hannan KM, Nguyen NN, et al
    Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.
    Blood. 2017 Mar 10. pii: blood-2016-05-718171. doi: 10.1182/blood-2016-05-718171
    PubMed     Text format     Abstract available


  15. RAHMAN S, Magnussen M, Leon TE, Farah N, et al
    Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia.
    Blood. 2017 Mar 7. pii: blood-2016-09-742148. doi: 10.1182/blood-2016-09-742148.
    PubMed     Text format     Abstract available


  16. LAL R, Lind K, Heitzer E, Ulz P, et al
    Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia.
    Blood. 2017 Mar 3. pii: blood-2016-11-751008. doi: 10.1182/blood-2016-11-751008.
    PubMed     Text format    


    February 2017
  17. TASIAN SK, Kenderian SS, Shen F, Ruella M, et al
    Optimized Depletion of Chimeric Antigen Receptor T-Cells in Murine Xenograft Models of Human Acute Myeloid Leukemia.
    Blood. 2017 Feb 28. pii: blood-2016-08-736041. doi: 10.1182/blood-2016-08-736041
    PubMed     Text format     Abstract available


  18. MONTALBAN-BRAVO G, Benton CB, Wang SA, Ravandi F, et al
    Greater than one TP53 abnormality is a dominant characteristic of pure erythroid leukemia.
    Blood. 2017 Feb 28. pii: blood-2016-11-749903. doi: 10.1182/blood-2016-11-749903
    PubMed     Text format    


  19. DANESHBOD Y, Medeiros LJ
    Dermal myeloid sarcoma as an initial presentation of acute myeloid leukemia.
    Blood. 2017;129:1056.
    PubMed     Text format    


  20. NAUDIN C, Hattabi A, Michelet F, Miri-Nezhad A, et al
    PUMILIO/FOXP1 signaling drives expansion of hematopoietic stem/progenitor and leukemia cells.
    Blood. 2017 Feb 23. pii: blood-2016-10-747436. doi: 10.1182/blood-2016-10-747436
    PubMed     Text format     Abstract available


  21. YOSHIZATO T, Nannya Y, Atsuta Y, Shiozawa Y, et al
    Impact of genetic alterations in stem-cell transplantation for myelodysplasia and secondary acute myeloid leukemia.
    Blood. 2017 Feb 21. pii: blood-2016-12-754796. doi: 10.1182/blood-2016-12-754796
    PubMed     Text format     Abstract available


  22. NAKATA Y, Ueda T, Nagamachi A, Yamasaki N, et al
    Acquired expression of CblQ367P in mice induces dysplastic myelopoiesis mimicking chronic myelomonocytic leukemia.
    Blood. 2017 Feb 16. pii: blood-2016-06-724658. doi: 10.1182/blood-2016-06-724658
    PubMed     Text format     Abstract available


  23. MILNE TA
    Mouse models of MLL leukemia: recapitulating the human disease.
    Blood. 2017 Feb 8. pii: blood-2016-10-691428. doi: 10.1182/blood-2016-10-691428.
    PubMed     Text format     Abstract available


  24. CAMPANA D, Pui CH
    Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.
    Blood. 2017 Feb 6. pii: blood-2016-12-725804. doi: 10.1182/blood-2016-12-725804.
    PubMed     Text format    


  25. THOMAS D, Majeti R
    Biology and relevance of human acute myeloid leukemia stem cells.
    Blood. 2017 Feb 3. pii: blood-2016-10-696054. doi: 10.1182/blood-2016-10-696054.
    PubMed     Text format     Abstract available


  26. HOLYOAKE TL, Vetrie D
    The chronic myeloid leukemia stem cell: stemming the tide of persistence.
    Blood. 2017 Feb 3. pii: blood-2016-09-696013. doi: 10.1182/blood-2016-09-696013.
    PubMed     Text format     Abstract available


  27. POLLYEA DA, Jordan CT
    Therapeutic targeting of acute myeloid leukemia stem cells.
    Blood. 2017 Feb 3. pii: blood-2016-10-696039. doi: 10.1182/blood-2016-10-696039.
    PubMed     Text format     Abstract available


  28. GODWIN CD, McDonald GB, Walter RB
    Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia.
    Blood. 2017 Feb 2. pii: blood-2017-01-762419. doi: 10.1182/blood-2017-01-762419.
    PubMed     Text format    


    January 2017
  29. ISHIZAWA J, Sugihara E, Kuninaka S, Mogushi K, et al
    FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B cell acute leukemia.
    Blood. 2017 Jan 31. pii: blood-2016-07-726216. doi: 10.1182/blood-2016-07-726216
    PubMed     Text format     Abstract available


  30. LAOUEDJ M, Tardif MR, Gil L, Raquil MA, et al
    S100A9 induces differentiation of acute myeloid leukemia cells through TLR4.
    Blood. 2017 Jan 30. pii: blood-2016-09-738005. doi: 10.1182/blood-2016-09-738005
    PubMed     Text format     Abstract available


  31. XU J, Li S
    Blasts with abundant cytoplasmic granules: acute myeloid leukemia or granular acute lymphoblastic leukemia?
    Blood. 2017;129:537.
    PubMed     Text format    


  32. GHIA P, Scarfo L, Perez S, Pathiraja K, et al
    Efficacy and safety of dinaciclib versus ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia.
    Blood. 2017 Jan 26. pii: blood-2016-10-748210. doi: 10.1182/blood-2016-10-748210
    PubMed     Text format    


  33. PYZER AR, Stroopinsky D, Rajabi H, Washington A, et al
    MUC1 mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia.
    Blood. 2017 Jan 26. pii: blood-2016-07-730614. doi: 10.1182/blood-2016-07-730614
    PubMed     Text format     Abstract available


  34. BOCHTLER T, Granzow M, Stolzel F, Kunz C, et al
    Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia.
    Blood. 2017 Jan 24. pii: blood-2016-09-738161. doi: 10.1182/blood-2016-09-738161
    PubMed     Text format     Abstract available


  35. MARKS DI, Rowntree C
    A review of the management of adults with T-cell acute lymphoblastic leukemia.
    Blood. 2017 Jan 23. pii: blood-2016-07-692608. doi: 10.1182/blood-2016-07-692608
    PubMed     Text format     Abstract available


  36. SANCHEZ-MARTIN M, Ferrando A
    The NOTCH1-MYC highway towards T-cell acute lymphoblastic leukemia.
    Blood. 2017 Jan 23. pii: blood-2016-09-692582. doi: 10.1182/blood-2016-09-692582
    PubMed     Text format     Abstract available


  37. LAMY T, Moignet A, Loughran TP Jr
    LGL leukemia: from pathogenesis to treatment.
    Blood. 2017 Jan 23. pii: blood-2016-08-692590. doi: 10.1182/blood-2016-08-692590
    PubMed     Text format     Abstract available


  38. WATANABE T
    Adult T-cell leukemia (ATL): molecular basis for clonal expansion and transformation of HTLV-1-infected T cells.
    Blood. 2017 Jan 23. pii: blood-2016-09-692574. doi: 10.1182/blood-2016-09-692574
    PubMed     Text format     Abstract available


  39. FINCH ER, Tukaramrao DB, Goodfield LL, Quickel MD, et al
    Activation of PPARgamma by endogenous prostaglandin J2 mediates the antileukemic effect of selenium in murine leukemia.
    Blood. 2017 Jan 23. pii: blood-2016-08-736405. doi: 10.1182/blood-2016-08-736405
    PubMed     Text format     Abstract available


  40. LANOCHA AA, Zdziarska B
    T-cell lymphoblastic leukemia with t(11;22)(q24;q12) and EWSR1 rearrangement.
    Blood. 2017;129:393.
    PubMed     Text format    


  41. DE WITTE T, Bowen D, Robin M, Malcovati L, et al
    Use of hematopoietic cell transplantation for patients with myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Blood. 2017 Jan 17. pii: blood-2016-06-724500. doi: 10.1182/blood-2016-06-724500
    PubMed     Text format    


  42. WOYACH JA
    How I manage ibrutinib-refractory chronic lymphocytic leukemia.
    Blood. 2017 Jan 17. pii: blood-2016-09-693598. doi: 10.1182/blood-2016-09-693598
    PubMed     Text format     Abstract available


  43. MANTHA S, Goldman DA, Devlin SM, Lee JW, et al
    Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.
    Blood. 2017 Jan 12. pii: blood-2016-10-747170. doi: 10.1182/blood-2016-10-747170
    PubMed     Text format     Abstract available


  44. GANZEL C, Reinus C
    Nerves in bone marrow of newly diagnosed therapy-related acute myeloid leukemia.
    Blood. 2017;129:268.
    PubMed     Text format    


  45. XU Z, Beaulieu Bergeron M
    Near-triploid B lymphoblastic leukemia with Burkitt-like morphology.
    Blood. 2017;129:267.
    PubMed     Text format    


  46. KHATER F, Lajoie M, Langlois S, Healy J, et al
    KMT2E-ASNS: a novel relapse-specific fusion gene in early T-cell precursor acute lymphoblastic leukemia.
    Blood. 2017 Jan 9. pii: blood-2016-10-744219. doi: 10.1182/blood-2016-10-744219.
    PubMed     Text format    


  47. GOOSSENS S, Peirs S, Van Loocke W, Wang J, et al
    Oncogenic ZEB2 activation drives sensitivity towards KDM1A inhibition in T-cell acute lymphoblastic leukemia.
    Blood. 2017 Jan 9. pii: blood-2016-06-721191. doi: 10.1182/blood-2016-06-721191.
    PubMed     Text format     Abstract available


  48. POURABDOLLAH M, Chang H
    Plasma cell neoplasm with plasmablastic morphology mimicking acute leukemia.
    Blood. 2017;129:132.
    PubMed     Text format    


  49. LIU J, Guo B, Chen Z, Wang N, et al
    miR-125b promotes MLL-AF9-driven murine acute myeloid leukemia involving a VEGFA-mediated non-cell-intrinsic mechanism.
    Blood. 2017 Jan 4. pii: blood-2016-06-721027. doi: 10.1182/blood-2016-06-721027.
    PubMed     Text format     Abstract available


  50. CAO M, Li T, He Z, Wang L, et al
    Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia.
    Blood. 2017 Jan 4. pii: blood-2016-09-739334. doi: 10.1182/blood-2016-09-739334.
    PubMed     Text format     Abstract available


  51. AHN IE, Underbayev C, Albitar A, Herman SE, et al
    Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.
    Blood. 2017 Jan 3. pii: blood-2016-06-719294. doi: 10.1182/blood-2016-06-719294.
    PubMed     Text format     Abstract available


    December 2016
  52. RAIMBAULT A, Chapuis N
    Plasma cell leukemia revealing a G6PD deficiency.
    Blood. 2016;128:3178.
    PubMed     Text format    



  53. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567-572.
    Blood. 2016;128:3017.
    PubMed     Text format    


  54. KIM E, Hurtz C, Koehrer S, Wang Z, et al
    Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.
    Blood. 2016 Dec 28. pii: blood-2016-06-722900. doi: 10.1182/blood-2016-06-722900
    PubMed     Text format     Abstract available


  55. MAXSON JE, Tyner JW
    Genomics of chronic neutrophilic leukemia.
    Blood. 2016 Dec 27. pii: blood-2016-10-695981. doi: 10.1182/blood-2016-10-695981
    PubMed     Text format     Abstract available



  56. Gallagher R, Collins S, Trujillo J, et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood. 1979;54(3):713-733.
    Blood. 2016;128:2871.
    PubMed     Text format    


  57. ABAZA Y, Kantarjian HM, Garcia-Manero G, Estey E, et al
    Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.
    Blood. 2016 Dec 21. pii: blood-2016-09-736686. doi: 10.1182/blood-2016-09-736686
    PubMed     Text format     Abstract available


  58. NISS ARFELT K, Barington L, Benned-Jensen T, Kubale V, et al
    EBI2 overexpression in mice leads to B1 B cell expansion and chronic lymphocytic leukemia-(CLL)-like B cell malignancies.
    Blood. 2016 Dec 21. pii: blood-2016-02-697185. doi: 10.1182/blood-2016-02-697185
    PubMed     Text format     Abstract available


  59. QU Y, Siggens L, Cordeddu L, Gaidzik VI, et al
    Cancer specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia.
    Blood. 2016 Dec 21. pii: blood-2016-07-726877. doi: 10.1182/blood-2016-07-726877
    PubMed     Text format     Abstract available



  60. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50(3):481-492.
    Blood. 2016;128:2745.
    PubMed     Text format    


  61. FRANCIS SS, Wallace AD, Wendt GA, Li L, et al
    In utero cytomegalovirus infection and development of childhood acute lymphoblastic leukemia.
    Blood. 2016 Dec 15. pii: blood-2016-07-723148.
    PubMed     Text format     Abstract available


  62. AUBERGER P, Puissant A
    Autophagy, a key mechanism of oncogenesis and resistance in leukemia.
    Blood. 2016 Dec 12. pii: blood-2016-07-692707.
    PubMed     Text format     Abstract available


  63. POWELL JA, Lewis AC, Zhu W, Toubia J, et al
    Targeting sphingosine kinase 1 induces MCL1 dependent cell death in acute myeloid leukemia.
    Blood. 2016 Dec 12. pii: blood-2016-06-720433.
    PubMed     Text format     Abstract available


  64. REA D, Nicolini FE, Tulliez M, Guilhot F, et al
    Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
    Blood. 2016 Dec 8. pii: blood-2016-09-742205.
    PubMed     Text format     Abstract available


  65. BUNTING MD, Varelias A, Souza-Fonseca-Guimaraes F, Schuster IS, et al
    GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity.
    Blood. 2016 Dec 7. pii: blood-2016-08-734020.
    PubMed     Text format     Abstract available


  66. JAIN N, Roberts KG, Jabbour E, Patel K, et al
    Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.
    Blood. 2016 Dec 5. pii: blood-2016-07-726588.
    PubMed     Text format     Abstract available


  67. LEONG SR, Sukumaran S, Hristopoulos M, Totpal K, et al
    An anti-CD3 / anti-CLL-1 Bispecific Antibody for the treatment of Acute Myeloid Leukemia.
    Blood. 2016 Dec 1. pii: blood-2016-08-735365.
    PubMed     Text format     Abstract available


    November 2016
  68. SAFAVI S, Paulsson K
    Near-haploid and low hypodiploid acute lymphoblastic leukemia - two distinct subtypes but consistently poor prognosis.
    Blood. 2016 Nov 30. pii: blood-2016-10-743765.
    PubMed     Text format     Abstract available


  69. GREVER MR, Abdel-Wahab O, Andritsos LA, Banerji V, et al
    Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
    Blood. 2016 Nov 30. pii: blood-2016-01-689422.
    PubMed     Text format     Abstract available


  70. THEUNISSEN P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, et al
    Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.
    Blood. 2016 Nov 30. pii: blood-2016-07-726307.
    PubMed     Text format     Abstract available


  71. GOTLIB J
    How I treat atypical chronic myeloid leukemia.
    Blood. 2016 Nov 29. pii: blood-2016-08-693630.
    PubMed     Text format     Abstract available



  72. Gill S, Tasian SK, Ruella M, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014;123(15):2343-2354.
    Blood. 2016;128:2585.
    PubMed     Text format    


  73. DANESHBOD Y, Medeiros LJ
    Pseudo Chediak-Higashi anomaly in acute monoblastic leukemia.
    Blood. 2016;128:2583.
    PubMed     Text format    


  74. THAKRAL B, Khoury JD
    Histiocytic sarcoma: secondary neoplasm or "transdifferentiation" in the setting of B-acute lymphoblastic leukemia.
    Blood. 2016;128:2475.
    PubMed     Text format    



  75. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49(4):511-533.
    Blood. 2016;128:2373.
    PubMed     Text format    


  76. CUI B, Ghia EM, Chen L, Rassenti LZ, et al
    High-level ROR1 associates with accelerated disease-progression in chronic lymphocytic leukemia.
    Blood. 2016 Nov 4. pii: blood-2016-04-712562.
    PubMed     Text format     Abstract available


  77. ZHANG J, Kong G, Rajagopalan A, Lu L, et al
    p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.
    Blood. 2016 Nov 4. pii: blood-2016-06-719237.
    PubMed     Text format     Abstract available


  78. GOLDBERG AD, Tallman MS
    Down for the count in acute myeloid leukemia.
    Blood. 2016;128:2195-2197.
    PubMed     Text format    


  79. RYAN CE, Sahaf B, Logan AC, O'Brien S, et al
    Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
    Blood. 2016 Nov 1. pii: blood-2016-06-715284.
    PubMed     Text format     Abstract available


    October 2016

  80. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219-234.
    Blood. 2016;128:2109.
    PubMed     Text format    


  81. BRAIG F, Brandt A, Goebeler M, Tony HP, et al
    Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking.
    Blood. 2016 Oct 26. pii: blood-2016-05-718395.
    PubMed     Text format     Abstract available


  82. MITANI K, Nagata Y, Sasaki K, Yoshida K, et al
    Somatic mosaicism in chronic myeloid leukemia in remission.
    Blood. 2016 Oct 26. pii: blood-2016-06-723494.
    PubMed     Text format    


  83. TASIAN SK, Teachey DT, Li Y, Shen F, et al
    Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Blood. 2016 Oct 24. pii: blood-2016-05-707653.
    PubMed     Text format     Abstract available



  84. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975;45(3):321-334.
    Blood. 2016;128:1995.
    PubMed     Text format    


  85. LI H, Mar BG, Zhang H, Puram RV, et al
    The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia.
    Blood. 2016 Oct 18. pii: blood-2016-05-714493.
    PubMed     Text format     Abstract available


  86. BOTTONI A, Rizzotto L, Lai TH, Liu C, et al
    Targeting BTK through microRNA in chronic lymphocytic leukemia.
    Blood. 2016 Oct 17. pii: blood-2016-07-727750.
    PubMed     Text format     Abstract available


  87. KIM T, Tyndel MS, Kim HJ, Ahn JS, et al
    Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy.
    Blood. 2016 Oct 12. pii: blood-2016-04-708560.
    PubMed     Text format     Abstract available


  88. ANTONELLI A, Noort WA, Jaques J, de Boer B, et al
    Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches.
    Blood. 2016 Oct 12. pii: blood-2016-05-719021.
    PubMed     Text format     Abstract available


  89. BALL M, List AF, Padron E
    When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia.
    Blood. 2016 Oct 5. pii: blood-2016-07-692988.
    PubMed     Text format     Abstract available


  90. MANCUSI A, Ruggeri L, Velardi A
    Haploidentical hematopoietic transplantation for the cure of leukemia: from its biology to clinical translation.
    Blood. 2016 Oct 3. pii: blood-2016-07-730564.
    PubMed     Text format     Abstract available


  91. ANDERSSON E, Tanahashi T, Sekiguchi N, Gasparini VR, et al
    High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia.
    Blood. 2016 Oct 3. pii: blood-2016-06-724856.
    PubMed     Text format    


    September 2016
  92. DAGKLIS A, Demeyer S, De Bie J, Radaelli E, et al
    Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors.
    Blood. 2016 Sep 30. pii: blood-2016-03-703454.
    PubMed     Text format     Abstract available



  93. Wang L, Man N, Sun X-J, et al. Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression. Blood. 2015;126(5):640-650.
    Blood. 2016;128:1778.
    PubMed     Text format    


  94. CHIANG MY, Wang Q, Gormley AC, Stein SJ, et al
    High selective pressure for Notch1 mutations that induce Myc in T cell acute lymphoblastic leukemia.
    Blood. 2016 Sep 26. pii: blood-2016-01-692855.
    PubMed     Text format     Abstract available


  95. KAJAL B, Chang H
    Acute myeloid leukemia with myelodysplasia-related changes demonstrating mixed-lineage phenotype.
    Blood. 2016;128:1663.
    PubMed     Text format    


  96. HU Z, Sun T
    Blastic plasmacytoid dendritic cell neoplasm associated with chronic myelomonocytic leukemia.
    Blood. 2016;128:1664.
    PubMed     Text format    


  97. KOTROVA M, Musilova A, Stuchly J, Fiser K, et al
    Distinct bilineal leukemia immunophenotypes are not genetically determined.
    Blood. 2016 Sep 13. pii: blood-2016-07-725861.
    PubMed     Text format    


  98. ZEBISCH A, Lal R, Muller M, Lind K, et al
    Acute myeloid leukemia with TP53 germline mutations.
    Blood. 2016 Sep 12. pii: blood-2016-08-732610.
    PubMed     Text format    


  99. DA CUNHA-BANG C, Christiansen I, Niemann CU
    The International prognostic Index for patients with chronic lymphocytic leukemia (CLL-IPI) applied in a population-based cohort.
    Blood. 2016 Sep 7. pii: blood-2016-07-724740.
    PubMed     Text format    


    August 2016
  100. DRUHAN LJ, McMahon DP, Steuerwald N, Price AE, et al
    Chronic neutrophilic leukemia in a child with a CSF3R T618I germline mutation.
    Blood. 2016 Aug 31. pii: blood-2016-07-730606.
    PubMed     Text format    


  101. FALINI B, Martelli MP, Tiacci E
    BRAF-V600E mutation in hairy cell leukemia: from bench to bedside.
    Blood. 2016 Aug 23. pii: blood-2016-07-418434.
    PubMed     Text format     Abstract available



  102. Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood. 1968;32(4):507-523.
    Blood. 2016;128:883.
    PubMed     Text format    


  103. FERREIRA TZ, Sandes AF
    Lymphocytosis, villi, and nucleoli: a variant of hairy cell leukemia.
    Blood. 2016;128:1018.
    PubMed     Text format    


  104. SPEEDY HE, Kinnersley B, Chubb D, Broderick P, et al
    Germline mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia.
    Blood. 2016 Aug 15. pii: blood-2016-01-695692.
    PubMed     Text format     Abstract available


  105. SUMITOMO Y, Koya J, Nakazaki K, Kataoka K, et al
    Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia.
    Blood. 2016 Aug 1. pii: blood-2015-12-684696.
    PubMed     Text format     Abstract available


    July 2016

  106. Dameshek W. Chronic lymphocytic leukemia-an accumulative disease of immunologically incompetent lymphocytes. Blood. 1967;29(4):566-584.
    Blood. 2016;128:465.
    PubMed     Text format    


  107. CAI Q, Jeannet R, Hua WK, Cook GJ, et al
    CBFbeta-SMMHC creates aberrant megakaryocyte-erythroid progenitors prone to leukemia-initiation in mice.
    Blood. 2016 Jul 21. pii: blood-2016-01-693119.
    PubMed     Text format     Abstract available


  108. HO TC, LaMere M, Stevens BM, Ashton JM, et al
    Evolution of acute myelogenous leukemia stem cell properties following treatment and progression.
    Blood. 2016 Jul 15. pii: blood-2016-02-695312.
    PubMed     Text format     Abstract available


  109. MIYOSHI H, Kiyasu J, Kato T, Yoshida N, et al
    PD-L1 expression on neoplastic or stromal cell is respectively poor or good prognostic factor for adult T-cell leukemia/lymphoma.
    Blood. 2016 Jul 14. pii: blood-2016-02-698936.
    PubMed     Text format     Abstract available


  110. MONTEWIS A, Eveillard M
    Acute myeloid leukemia with erythrophagocytosis indicative of KAT6A rearrangement.
    Blood. 2016;128:314.
    PubMed     Text format    


  111. ZHU H, Hu J, Chen L, Zhou W, et al
    The 12-year follow-up of survival, chronic adverse effects and retention of arsenic in patients with acute promyelocytic leukemia.
    Blood. 2016 Jul 11. pii: blood-2016-02-699439.
    PubMed     Text format    


  112. WOLLESCHAK D, Heidel FH
    Chronic myelogenous leukemia evolving after treatment of multiple myeloma.
    Blood. 2016;128:146.
    PubMed     Text format    


  113. ELENA C, Galli A, Such E, Meggendorfer M, et al
    Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.
    Blood. 2016 Jul 6. pii: blood-2016-05-714030.
    PubMed     Text format     Abstract available


    June 2016

  114. Whang J, Frei E III, Tjio JH, Carbone PP, Brecher G. The distribution of the Philadelphia chromosome in patients with chronic myelogenous leukemia. Blood. 1963;22(6):664-673.
    Blood. 2016;127:3295.
    PubMed     Text format    


  115. THOMPSON MP, Waters TM, Kaplan EK, McKillop CN, et al
    Hospital volume and acute myeloid leukemia mortality in Medicare beneficiaries aged 65 and older.
    Blood. 2016 Jun 29. pii: blood-2016-05-716662.
    PubMed     Text format    


  116. LIBOUREL EJ, Klerk CP, van Norden Y, de Maat MP, et al
    Disseminated intravascular coagulation at diagnosis is a strong predictor for both arterial and venous thrombosis in newly diagnosed acute myeloid leukemia.
    Blood. 2016 Jun 28. pii: blood-2016-02-701094.
    PubMed     Text format     Abstract available


  117. RASHIDI A, Walter RB, Tallman MS, Appelbaum FR, et al
    Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.
    Blood. 2016 Jun 27. pii: blood-2016-03-674127.
    PubMed     Text format    


  118. RAU RE, Rodriguez B, Luo M, Jeong M, et al
    DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
    Blood. 2016 Jun 22. pii: blood-2015-11-684225.
    PubMed     Text format     Abstract available


  119. LEIVA-JUAREZ MM, Ware HH, Kulkarni VV, Zweidler-McKay PA, et al
    Inducible epithelial resistance protects mice against leukemia-associated pneumonia.
    Blood. 2016 Jun 17. pii: blood-2016-03-708511.
    PubMed     Text format     Abstract available


  120. KOSCIUCZUK EM, Saleiro D, Kroczynska B, Beauchamp EM, et al
    Merestinib blocks MNK kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo.
    Blood. 2016 Jun 15. pii: blood-2016-02-698704.
    PubMed     Text format     Abstract available


  121. METZELER KH, Herold T, Rothenberg-Thurley M, Amler S, et al
    Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
    Blood. 2016 Jun 10. pii: blood-2016-01-693879.
    PubMed     Text format     Abstract available


  122. GREVER MR
    BRAF inhibitor: targeted therapy in hairy cell leukemia.
    Blood. 2016;127:2784-5.
    PubMed     Text format    


  123. PIYA S, Kornblau SM, Ruvolo VR, Mu H, et al
    Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia.
    Blood. 2016 Jun 7. pii: blood-2016-01-692244.
    PubMed     Text format     Abstract available


    May 2016
  124. LAMPSON BL, Kasar SN, Matos TR, Morgan EA, et al
    Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.
    Blood. 2016 May 31. pii: blood-2016-03-707133.
    PubMed     Text format     Abstract available


  125. SHORT NJ, Jabbour E, Sasaki K, Patel K, et al
    Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Blood. 2016 May 27. pii: blood-2016-03-707562.
    PubMed     Text format     Abstract available


  126. THIJSSEN R, Ter Burg J, Garrick B, van Bochove GG, et al
    Dual TORK/DNA-PK inhibition blocks critical signalling pathways in chronic lymphocytic leukemia.
    Blood. 2016 May 27. pii: blood-2016-02-700328.
    PubMed     Text format     Abstract available


  127. OFRAN Y, Tallman MS, Rowe JM
    How I treat acute myeloid leukemia presenting with preexisting comorbidities.
    Blood. 2016 May 27. pii: blood-2016-01-635060.
    PubMed     Text format     Abstract available


  128. THORNE SH
    Virus fuels NK cell killing of leukemia.
    Blood. 2016;127:2509.
    PubMed     Text format    


  129. GUO B, Zhang L, Chiorazzi N, Rothstein TL, et al
    IL-4 rescues surface IgM expression in chronic lymphocytic leukemia.
    Blood. 2016 May 25. pii: blood-2015-11-682997.
    PubMed     Text format     Abstract available


  130. ELMAAGACLI AH, Koldehoff M
    Cytomegalovirus replication reduces the relapse incidence in patients with acute myeloid leukemia.
    Blood. 2016 May 23. pii: blood-2016-04-713644.
    PubMed     Text format    


  131. HANDGRETINGER R, Lang P, Andre MC
    Exploitation of Natural Killer (NK) cells for the treatment of acute leukemia.
    Blood. 2016 May 20. pii: blood-2015-12-629055.
    PubMed     Text format     Abstract available


  132. BAHMANYAR M, Chang H
    Acute myeloid leukemia with myelodysplasia-related changes demonstrating prominent basophilic differentiation.
    Blood. 2016;127:2503.
    PubMed     Text format    


  133. RASHIDI A, Fisher SI
    EBV-associated aggressive natural killer cell leukemia.
    Blood. 2016;127:2502.
    PubMed     Text format    


  134. MOORE EM, Roth CG
    Plasma cell leukemia mimicking acute myeloid leukemia.
    Blood. 2016;127:2359.
    PubMed     Text format    



  135. Heyssel R, Brill AB, Woodbury LA, et al. Leukemia in Hiroshima atomic bomb survivors. Blood. 1960;15(3):313-331.
    Blood. 2016;127:2165.
    PubMed     Text format    


    April 2016
  136. SMALLWOOD DT, Apollonio B, Willimott S, Lezina L, et al
    Extracellular vesicles released by CD40/IL-4 stimulated chronic lymphocytic leukemia cells confer altered functional properties to CD4+ T cells.
    Blood. 2016 Apr 26. pii: blood-2015-11-682377.
    PubMed     Text format     Abstract available


  137. MA HS, Greenblatt SM, Shirley CM, Duffield AS, et al
    All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
    Blood. 2016 Apr 21. pii: blood-2015-05-646786.
    PubMed     Text format     Abstract available


  138. WILLIAMS MT, Yousafzai YM, Elder A, Rehe K, et al
    The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts.
    Blood. 2016;127:1998-2006.
    PubMed     Text format     Abstract available


  139. MICHEL G, Galambrun C, Sirvent A, Pochon C, et al
    Single versus double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome.
    Blood. 2016 Apr 20. pii: blood-2016-01-694349.
    PubMed     Text format     Abstract available


  140. JOHNSON SM, Dempsey C, Chadwick A, Harrison S, et al
    Metabolic reprogramming of bone marrow stromal cells by leukemic extracellular vesicles in acute lymphoblastic leukemia.
    Blood. 2016 Apr 20. pii: blood-2015-12-688051.
    PubMed     Text format    


  141. PARKER WT, Yeung DT, Yeoman AL, Altamura HK, et al
    The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
    Blood. 2016;127:1870-80.
    PubMed     Text format     Abstract available


  142. ARBER DA, Orazi A, Hasserjian R, Thiele J, et al
    The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia.
    Blood. 2016 Apr 11. pii: blood-2016-03-643544.
    PubMed     Text format     Abstract available


  143. BAZARBACHI A
    Tax fingerprint in adult T-cell leukemia.
    Blood. 2016;127:1737-8.
    PubMed     Text format    


  144. PARIKH SA, Strati P, Tsang M, West CP, et al
    Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis.
    Blood. 2016;127:1752-60.
    PubMed     Text format     Abstract available


  145. GU S, Chan WW, Mohi G, Rosenbaum J, et al
    Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
    Blood. 2016;127:1803-13.
    PubMed     Text format     Abstract available


    March 2016

  146. Frei E III, Holland JF, Schneiderman MA, et al. A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood. 1958;13(12):1126-1148.
    Blood. 2016;127:1621.
    PubMed     Text format    


  147. REDELL MS
    A STAT3 decoy lures AML out of hiding.
    Blood. 2016;127:1628-9.
    PubMed     Text format     Abstract available



  148. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13(7):609-630.
    Blood. 2016;127:1519.
    PubMed     Text format     Abstract available


  149. LUSKIN MR, Lee JW, Fernandez HF, Abdel-Wahab O, et al
    Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.
    Blood. 2016;127:1551-8.
    PubMed     Text format     Abstract available


  150. SCHULZE I, Rohde C, Scheller-Wendorff M, Baumer N, et al
    Increased DNA methylation of Dnmt3b targets impairs leukemogenesis.
    Blood. 2016;127:1575-86.
    PubMed     Text format     Abstract available


  151. STANLEY RF, Steidl U
    Ectopic DNMT3B expression delays leukemogenesis.
    Blood. 2016;127:1525-6.
    PubMed     Text format     Abstract available


  152. BABA T, Tanabe Y, Yoshikawa S, Yamanishi Y, et al
    MIP-1alpha/CCL3-expressing basophil-lineage cells drive the leukemic hematopoiesis of chronic myeloid leukemia in mice.
    Blood. 2016 Mar 22. pii: blood-2015-10-673087.
    PubMed     Text format     Abstract available


  153. WANG W, Cortes JE, Tang G, Khoury JD, et al
    Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
    Blood. 2016 Mar 22. pii: blood-2016-01-690230.
    PubMed     Text format     Abstract available


  154. WANQUET A, Birsen R, Lemal R, Hunault M, et al
    Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.
    Blood. 2016 Mar 18. pii: blood-2016-02-697193.
    PubMed     Text format    


  155. KADIA TM
    Release the hounds: virotherapy with immunotherapy.
    Blood. 2016;127:1381-3.
    PubMed     Text format     Abstract available


  156. DUPLOYEZ N, Marceau-Renaut A, Boissel N, Petit A, et al
    Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
    Blood. 2016 Mar 15. pii: blood-2015-12-688705.
    PubMed     Text format     Abstract available


  157. NEESON P
    Allogeneic CAR19 cells clear ALL.
    Blood. 2016;127:1224-5.
    PubMed     Text format     Abstract available



  158. Rosenthal MC, Pisciotta AV, Komninos ZD, Goldenberg H, Dameshek W. The auto-immune hemolytic anemia of malignant lymphocytic disease. Blood. 1955;10(3):197-227.
    Blood. 2016;127:1217.
    PubMed     Text format    


  159. JACOBY E, Yang Y, Qin H, Chien CD, et al
    Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.
    Blood. 2016;127:1361-70.
    PubMed     Text format     Abstract available


  160. MAN N, Sun XJ, Tan Y, Garcia-Cao M, et al
    Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin.
    Blood. 2016 Mar 4. pii: blood-2015-11-677708.
    PubMed     Text format     Abstract available


  161. DIETRICH S, Pircher A, Endris V, Peyrade F, et al
    BRAF inhibition in hairy cell leukemia with low dose vemurafenib.
    Blood. 2016 Mar 3. pii: blood-2015-11-680074.
    PubMed     Text format     Abstract available


    February 2016
  162. OLOMBEL G, Guerin E, Guy J, Perrot JY, et al
    The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.
    Blood. 2016 Feb 29. pii: blood-2016-01-689976.
    PubMed     Text format    


  163. CHEN Z, Hu S
    MYC/BCL2 double-hit lymphoma/leukemia mimicking acute leukemia at initial presentation.
    Blood. 2016;127:1072.
    PubMed     Text format    


  164. TAWANA K, Fitzgibbon J
    Inherited DDX41 mutations: 11 genes and counting.
    Blood. 2016;127:960-1.
    PubMed     Text format    


  165. BLACHLY JS
    Ribosomal revelation.
    Blood. 2016;127:958-9.
    PubMed     Text format    


  166. LEWINSOHN M, Brown AL, Weinel LM, Phung C, et al
    Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies.
    Blood. 2016;127:1017-23.
    PubMed     Text format     Abstract available


  167. MARCUCCI G, Li L
    Not only TKI! Targeting FLT3-ITD by autophagy.
    Blood. 2016;127:796-7.
    PubMed     Text format    


  168. WONG TN, Miller CA, Klco JM, Petti A, et al
    Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML.
    Blood. 2016;127:893-7.
    PubMed     Text format     Abstract available


  169. LARRUE C, Saland E, Boutzen H, Vergez F, et al
    Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.
    Blood. 2016;127:882-92.
    PubMed     Text format     Abstract available


  170. DEININGER MW, Hodgson JG, Shah NP, Cortes JE, et al
    Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
    Blood. 2016;127:703-12.
    PubMed     Text format     Abstract available


  171. SAGLIO G, Fava C
    BCR-ABL1 mutation not equal ponatinib resistance.
    Blood. 2016;127:666-7.
    PubMed     Text format    


  172. MARTINEZ-TRILLOS A, Navarro A, Aymerich M, Delgado J, et al
    Clinical impact of MYD88 mutations in chronic lymphocytic leukemia.
    Blood. 2016 Feb 4. pii: blood-2015-10-678490.
    PubMed     Text format    


  173. ISHIKAWA S
    Opposite RHOA functions within the ATLL category.
    Blood. 2016;127:524-5.
    PubMed     Text format     Abstract available


  174. NADEU F, Delgado J, Royo C, Baumann T, et al
    Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1 and ATM mutations in chronic lymphocytic leukemia.
    Blood. 2016 Feb 2. pii: blood-2015-07-659144.
    PubMed     Text format     Abstract available


  175. PABST C, Bergeron A, Lavallee VP, Yeh J, et al
    GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo.
    Blood. 2016 Feb 1. pii: blood-2015-11-683649.
    PubMed     Text format     Abstract available


    January 2016
  176. VALSECCHI R, Coltella N, Belloni D, Ponente M, et al
    HIF-1alpha regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment.
    Blood. 2016 Jan 29. pii: blood-2015-07-657056.
    PubMed     Text format     Abstract available


  177. PAGGETTI J, Moussay E
    BCR engagement in CLL: when translation goes wrong.
    Blood. 2016;127:378-80.
    PubMed     Text format     Abstract available


  178. MAUS MV
    Innate immune signaling in CLL.
    Blood. 2016;127:376-8.
    PubMed     Text format     Abstract available


  179. WALTER HS, Rule SA, Dyer MJ, Karlin L, et al
    A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
    Blood. 2016;127:411-9.
    PubMed     Text format     Abstract available


  180. WAGNER M, Oelsner M, Moore A, Gotte F, et al
    Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia.
    Blood. 2016;127:436-48.
    PubMed     Text format     Abstract available


  181. BELLON M, Lu L, Nicot C
    Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia.
    Blood. 2016 Jan 26. pii: blood-2015-11-685032.
    PubMed     Text format     Abstract available


  182. FRAIETTA JA, Beckwith KA, Patel PR, Ruella M, et al
    Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood. 2016 Jan 26. pii: blood-2015-11-679134.
    PubMed     Text format     Abstract available


  183. ZHANG Q, Hossain DM, Duttagupta P, Moreira D, et al
    Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.
    Blood. 2016 Jan 21. pii: blood-2015-08-665604.
    PubMed     Text format     Abstract available



  184. Farber S. Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. Blood. 1949;4(2):160-167.
    Blood. 2016;127:271.
    PubMed     Text format    


  185. AWAN FT
    Cure for CLL?
    Blood. 2016;127:274.
    PubMed     Text format    


  186. THOMPSON PA, Wierda WG
    Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.
    Blood. 2016;127:279-86.
    PubMed     Text format     Abstract available


  187. LIBURA M, Giebel S, Piatkowska-Jakubas B, Pawelczyk M, et al
    Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients.
    Blood. 2016;127:360-2.
    PubMed     Text format    


  188. FUJIKAWA D, Nakagawa S, Hori M, Kurokawa N, et al
    Polycomb-dependent epigenetic landscape in adult T-cell leukemia.
    Blood. 2016 Jan 15. pii: blood-2015-08-662593.
    PubMed     Text format     Abstract available


  189. MINUCCI S
    DNA binding modes of leukemia oncoproteins.
    Blood. 2016;127:177-8.
    PubMed     Text format    


  190. ARNOUX I, Loosveld M
    Hepatosplenic T-cell lymphoma: an acute leukemia presentation.
    Blood. 2016;127:269.
    PubMed     Text format    


  191. WOYACH JA
    FCR holds up to the test of time: CLL8 follow-up.
    Blood. 2016;127:172-3.
    PubMed     Text format    


  192. LIU J, Zhu HH, Jiang H, Jiang Q, et al
    Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.
    Blood. 2016;127:243-50.
    PubMed     Text format     Abstract available


  193. FISCHER K, Bahlo J, Fink AM, Goede V, et al
    Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
    Blood. 2016;127:208-15.
    PubMed     Text format     Abstract available


  194. MIRANTES C, Dosil MA, Hills D, Yang J, et al
    Deletion of Pten in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma, but not myeloid malignancies.
    Blood. 2016 Jan 14. pii: blood-2015-09-669036.
    PubMed     Text format     Abstract available


  195. JAIN N, Lamb AE, O'Brien S, Ravandi F, et al
    Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.
    Blood. 2016 Jan 8. pii: blood-2015-08-661702.
    PubMed     Text format     Abstract available


  196. BURGER JA
    Obinutuzumab: the more the merrier?
    Blood. 2016;127:6-8.
    PubMed     Text format     Abstract available


  197. STEIN EM, Tallman MS
    Emerging therapeutic drugs for AML.
    Blood. 2016;127:71-8.
    PubMed     Text format     Abstract available


  198. AL-HUSSAINI M, Rettig MP, Ritchey JK, Karpova D, et al
    Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.
    Blood. 2016;127:122-31.
    PubMed     Text format     Abstract available


  199. JAIN P, Kantarjian H, Patel KP, Nogueras Gonzalez G, et al
    Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Blood. 2016 Jan 4. pii: blood-2015-10-674242.
    PubMed     Text format     Abstract available


    December 2015
  200. HELSMOORTEL HH, Bresolin S, Lammens T, Cave H, et al
    LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia.
    Blood. 2015 Dec 28. pii: blood-2015-09-667808.
    PubMed     Text format     Abstract available


  201. SHEN W, Patnaik MM, Ruiz A, Russell SJ, et al
    Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
    Blood. 2015 Dec 28. pii: blood-2015-06-652503.
    PubMed     Text format     Abstract available


  202. ISLAM P, Daniel C, Strelec L, Kaye AH, et al
    Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.
    Blood. 2015 Dec 23. pii: blood-2015-12-686873.
    PubMed     Text format    


  203. LJUNGSTROM V, Cortese D, Young E, Pandzic T, et al
    Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
    Blood. 2015 Dec 16. pii: blood-2015-10-674572.
    PubMed     Text format     Abstract available


  204. WOUTERS BJ, Delwel R
    Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.
    Blood. 2015 Dec 10. pii: blood-2015-07-604512.
    PubMed     Text format     Abstract available


  205. GRIMWADE D, Ivey A, Huntly BJ
    Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.
    Blood. 2015 Dec 10. pii: blood-2015-07-604496.
    PubMed     Text format     Abstract available


  206. LOWENBERG B, Rowe JM
    Introduction to the Review Series on Advances in Acute Myeloid Leukemia (AML).
    Blood. 2015 Dec 10. pii: blood-2015-10-662684.
    PubMed     Text format    


  207. DOMBRET H, Gardin C
    An update of current treatments for adult acute myeloid leukemia.
    Blood. 2015 Dec 10. pii: blood-2015-08-604520.
    PubMed     Text format     Abstract available


  208. CORNELISSEN JJ, Blaise D
    Hematopoietic stem cell transplantation for patients with AML in first CR.
    Blood. 2015 Dec 10. pii: blood-2015-07-604546.
    PubMed     Text format     Abstract available


  209. UTTARKAR S, Dasse E, Coulibaly A, Steinmann S, et al
    Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.
    Blood. 2015 Dec 2. pii: blood-2015-09-668632.
    PubMed     Text format     Abstract available


    November 2015
  210. KUCINE N, Marubayashi S, Bhagwat N, Papalexi E, et al
    Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.
    Blood. 2015;126:2479-83.
    PubMed     Text format     Abstract available


  211. KAROL SE, Mattano LA Jr, Yang W, Maloney KW, et al
    Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia.
    Blood. 2015 Nov 20. pii: blood-2015-10-673848.
    PubMed     Text format     Abstract available


  212. LIU H, Sun X
    Pleomorphic plasma cell leukemia.
    Blood. 2015;126:2436.
    PubMed     Text format    


  213. LARSON RA
    Is there a best TKI for chronic phase CML?
    Blood. 2015;126:2370-5.
    PubMed     Text format     Abstract available


  214. STEENSMA DP
    Cytopenias + mutations - dysplasia = what?
    Blood. 2015;126:2349-51.
    PubMed     Text format    


  215. MATTHEWS GM, Mehdipour P, Cluse LA, Falkenberg KJ, et al
    Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
    Blood. 2015;126:2392-403.
    PubMed     Text format     Abstract available


  216. CARGO CA, Rowbotham N, Evans PA, Barrans SL, et al
    Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression.
    Blood. 2015;126:2362-5.
    PubMed     Text format     Abstract available


  217. VERHAGEN HJ, Smit MA, Rutten A, Denkers F, et al
    Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all trans retinoic acid.
    Blood. 2015 Nov 18. pii: blood-2015-07-653840.
    PubMed     Text format     Abstract available


  218. OROZCO JJ, Kenoyer A, Balkin ER, Gooley TA, et al
    Anti-CD45 radioimmunotherapy without TBI before BMT facilitates persistent haploidentical donor engraftment in a murine model.
    Blood. 2015 Nov 17. pii: blood-2014-12-617019.
    PubMed     Text format     Abstract available


  219. NAGATA Y, Kontani K, Enami T, Kataoka K, et al
    Variegated RHOA mutations in adult T-cell leukemia/lymphoma.
    Blood. 2015 Nov 16. pii: blood-2015-06-644948.
    PubMed     Text format     Abstract available


  220. KWOK M, Davies N, Agathanggelou A, Smith E, et al
    ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53 or ATM defective chronic lymphocytic leukemia cells.
    Blood. 2015 Nov 12. pii: blood-2015-05-644872.
    PubMed     Text format     Abstract available


  221. ARANGO M
    Adult T-cell leukemia/lymphoma.
    Blood. 2015;126:2343.
    PubMed     Text format    


  222. LI Y, Wang H, Wang X, Jin W, et al
    Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.
    Blood. 2015 Nov 6. pii: blood-2015-03-626671.
    PubMed     Text format     Abstract available


  223. BOSCH F, Abrisqueta P
    Ibrutinib in CLL: 2 sides of the same coin.
    Blood. 2015;126:2173-4.
    PubMed     Text format    


    October 2015
  224. ZENZ T, Huber W
    Mutational landscape and complexity in CLL.
    Blood. 2015;126:2078-9.
    PubMed     Text format    


  225. GUIEZE R, Robbe P, Clifford R, de Guibert S, et al
    Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
    Blood. 2015;126:2110-7.
    PubMed     Text format     Abstract available


  226. HIJIYA N, Schultz KR, Metzler M, Millot F, et al
    Pediatric chronic myeloid leukemia is a unique disease that requires a different approach.
    Blood. 2015 Oct 28. pii: blood-2015-06-648667.
    PubMed     Text format     Abstract available


  227. HALPERN AB, Lyman GH, Walsh TJ, Kontoyiannis DP, et al
    Evidence-based focused review of primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.
    Blood. 2015 Oct 26. pii: blood-2015-07-627323.
    PubMed     Text format    


  228. THOMPSON PA, Tam CS, O'Brien SM, Wierda WG, et al
    Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
    Blood. 2015 Oct 22. pii: blood-2015-09-667675.
    PubMed     Text format     Abstract available


  229. CHURPEK JE, Pyrtel K, Kanchi KL, Shao J, et al
    Genomic analysis of germline and somatic variants in familial myelodysplasia/acute myeloid leukemia.
    Blood. 2015 Oct 22. pii: blood-2015-04-641100.
    PubMed     Text format     Abstract available


  230. LANDGREN O
    No CLL transmission through blood transfusion.
    Blood. 2015;126:1978-9.
    PubMed     Text format     Abstract available


  231. LI Z, Chen P, Su R, Li Y, et al
    Overexpression and knockout of miR-126 both promote leukemogenesis.
    Blood. 2015;126:2005-15.
    PubMed     Text format     Abstract available


  232. SCHMID C, Labopin M, Socie G, Daguindau E, et al
    Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.
    Blood. 2015;126:2062-9.
    PubMed     Text format     Abstract available


  233. YEOMANS A, Thirdborough SM, Valle-Argos B, Linley A, et al
    Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.
    Blood. 2015 Oct 21. pii: blood-2015-07-660969.
    PubMed     Text format     Abstract available


  234. ZUGMAIER G, Gokbuget N, Klinger M, Viardot A, et al
    Long-term survival and T-Cell kinetics in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia who achieved minimal residual disease response following treatment with Anti-CD19 BiTE(R) antibody construct blinatumomab.
    Blood. 2015 Oct 19. pii: blood-2015-06-649111.
    PubMed     Text format     Abstract available


  235. BYRD JC, Flynn J, Kipps TJ, Boxer M, et al
    Randomized phase II study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia (CLL).
    Blood. 2015 Oct 15. pii: blood-2015-03-634394.
    PubMed     Text format     Abstract available


  236. O'BRIEN SM, Lamanna N, Kipps TJ, Flinn I, et al
    A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia.
    Blood. 2015 Oct 15. pii: blood-2015-03-630947.
    PubMed     Text format     Abstract available


  237. DEBORD C, Eveillard M
    Leukemic phase of a large B-cell lymphoma arising in KSHV-associated multicentric Castleman disease.
    Blood. 2015;126:1966.
    PubMed     Text format    


  238. EVEILLARD M, Moreau P
    Atypical plasma cell leukemia mistaken for lymphocytosis on blood count.
    Blood. 2015;126:1965.
    PubMed     Text format    


  239. SAMUDIO I, Konopleva M
    Targeting leukemia's "fatty tooth".
    Blood. 2015;126:1874-5.
    PubMed     Text format     Abstract available


  240. DEARDEN C
    So FCR, so good.
    Blood. 2015;126:1872-4.
    PubMed     Text format     Abstract available


  241. SANJUAN-PLA A, Bueno C, Prieto C, Acha P, et al
    Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.
    Blood. 2015 Oct 13. pii: blood-2015-09-667378.
    PubMed     Text format     Abstract available


  242. EFFICACE F, Mandelli F, Platzbecker U, Cottone F, et al
    Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia.
    Blood. 2015 Oct 9. pii: blood-2015-07-658922.
    PubMed     Text format    


  243. LOBRY C
    Restoring Ikaros's wings to solve a leukemia maze.
    Blood. 2015;126:1735-6.
    PubMed     Text format    


  244. GAYNON PS
    ALL and osteonecrosis.
    Blood. 2015;126:1734-5.
    PubMed     Text format     Abstract available


  245. MOROY T, Vassen L, Wilkes B, Khandanpour C, et al
    From cytopenia to leukemia: the role of Gfi1 and Gfi1b in blood formation.
    Blood. 2015 Oct 7. pii: blood-2015-06-655043.
    PubMed     Text format     Abstract available


  246. GARG M, Nagata Y, Kanojia D, M T A, et al
    Profiling of somatic mutations of acute myeloid leukemia, FLT3-ITD subgroup at diagnosis and relapse.
    Blood. 2015 Oct 5. pii: blood-2015-05-646240.
    PubMed     Text format     Abstract available


  247. LUCENA-ARAUJO AR, Kim HT, Thome C, Jacomo RH, et al
    High DeltaNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia.
    Blood. 2015 Oct 1. pii: blood-2015-01-623330.
    PubMed     Text format     Abstract available


  248. HWANG IS, Shin S, Min YH, Lee ST, et al
    NOTCH2 missplicing can occur in relation to apoptosis.
    Blood. 2015;126:1731-2.
    PubMed     Text format    


  249. PLESA A, Sujobert P
    This is not an erythroblast.
    Blood. 2015;126:1729.
    PubMed     Text format    


    September 2015
  250. OSHIMA M, Iwama A
    Nuclear, not cytoplasmic, PKR maneuvers in AML.
    Blood. 2015;126:1523-4.
    PubMed     Text format     Abstract available


  251. SPERLAZZA J, Rahmani M, Beckta J, Aust M, et al
    Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation.
    Blood. 2015;126:1462-72.
    PubMed     Text format     Abstract available


  252. ORTUNO FJ, Sola M
    Extreme dyserythropoiesis in the setting of acute erythroid leukemia.
    Blood. 2015;126:1391.
    PubMed     Text format    


  253. EMADI A
    Exploiting AML vulnerability: glutamine dependency.
    Blood. 2015;126:1269-70.
    PubMed     Text format    


  254. CALIGARIS-CAPPIO F
    Directing CLL-cell traffic.
    Blood. 2015;126:1267-8.
    PubMed     Text format    


  255. SERODY J
    GVHD and miR: good things in small packages.
    Blood. 2015;126:1265-7.
    PubMed     Text format    


  256. MUKHERJEE S
    "Blood feuds".
    Blood. 2015;126:1264-5.
    PubMed     Text format    


  257. OCHODNICKA-MACKOVICOVA K, Bahjat M, Bloedjes TA, Maas C, et al
    NF-kappaB and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activity.
    Blood. 2015;126:1324-35.
    PubMed     Text format     Abstract available


  258. SUN C, Tian X, Lee YS, Gunti S, et al
    Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.
    Blood. 2015 Sep 3. pii: blood-2015-04-639203.
    PubMed     Text format     Abstract available


  259. FULDA S
    Biomarker of sensitivity to PR-104 in leukemia.
    Blood. 2015;126:1153-4.
    PubMed     Text format    


    August 2015
  260. JONES CL, Gearheart CM, Fosmire S, Delgado-Martin C, et al
    MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.
    Blood. 2015 Aug 31. pii: blood-2015-04-639138.
    PubMed     Text format     Abstract available


  261. ARNAUD MP, Vallee A, Robert G, Bonneau J, et al
    CD9, a key actor in the dissemination of lymphoblastic leukemia, modulating CXCR4-mediated migration via RAC1 signaling.
    Blood. 2015 Aug 28. pii: blood-2015-02-628560.
    PubMed     Text format     Abstract available


  262. LIMA AS, de Mello MR, Fernandes E, Bezerra MF, et al
    Clinical outcomes of patients with acute myeloid leukemia: evaluation of genetic and molecular findings in a real-life setting.
    Blood. 2015 Aug 28. pii: blood-2015-07-657551.
    PubMed     Text format    


  263. SONG JY, Popplewell L
    Circulating reactive plasma cells in the setting of peripheral T-cell lymphoma mimicking plasma cell leukemia.
    Blood. 2015;126:1150.
    PubMed     Text format    


  264. APOLLONIO B, Ramsay AG
    Exosomes and CAFs: partners in crime.
    Blood. 2015;126:1053-5.
    PubMed     Text format     Abstract available


  265. MAHIEUX R
    A vaccine against HTLV-1 HBZ makes sense.
    Blood. 2015;126:1052-3.
    PubMed     Text format     Abstract available


  266. SUGATA K, Yasunaga J, Mitobe Y, Miura M, et al
    Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor.
    Blood. 2015;126:1095-105.
    PubMed     Text format     Abstract available


  267. BUECHELE C, Breese EH, Schneidawind D, Lin CH, et al
    MLL leukemia induction by genome editing of human CD34+ hematopoietic cells.
    Blood. 2015 Aug 26. pii: blood-2015-05-646398.
    PubMed     Text format     Abstract available


  268. HJALGRIM H, Rostgaard K, Vasan SK, Ullum H, et al
    No evidence of transmission of chronic lymphocytic leukemia through blood transfusion.
    Blood. 2015 Aug 24. pii: blood-2015-03-632844.
    PubMed     Text format     Abstract available


  269. POLAK R, de Rooij B, Pieters R, den Boer ML, et al
    B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment.
    Blood. 2015 Aug 21. pii: blood-2015-03-634238.
    PubMed     Text format     Abstract available


  270. ROBAK T, Smolewski P
    New mutation in hairy cell leukemia.
    Blood. 2015;126:930-1.
    PubMed     Text format    


  271. KOTROVA M, Muzikova K, Mejstrikova E, Novakova M, et al
    The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL.
    Blood. 2015;126:1045-7.
    PubMed     Text format    


  272. BALIAKAS P, Hadzidimitriou A, Agathangelidis A, Rossi D, et al
    Prognostic relevance of MYD88 mutations in CLL: the jury is still out.
    Blood. 2015;126:1043-4.
    PubMed     Text format    


  273. ASTER JC
    Dicing up T-ALL.
    Blood. 2015;126:929-30.
    PubMed     Text format     Abstract available


  274. STAUSS HJ
    Engineered T cells can fight malignant T cells.
    Blood. 2015;126:927-8.
    PubMed     Text format     Abstract available


  275. BOROWITZ MJ, Wood BL, Devidas M, Loh ML, et al
    Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.
    Blood. 2015;126:964-71.
    PubMed     Text format     Abstract available


  276. MAMONKIN M, Rouce RH, Tashiro H, Brenner MK, et al
    A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.
    Blood. 2015;126:983-92.
    PubMed     Text format     Abstract available


  277. JUNKER F, Chabloz A, Koch U, Radtke F, et al
    Dicer1 imparts essential survival cues in Notch-driven T-ALL via miR-21-mediated tumor suppressor Pdcd4 repression.
    Blood. 2015;126:993-1004.
    PubMed     Text format     Abstract available


  278. ROSSI D, Terzi-di-Bergamo L, De Paoli L, Cerri M, et al
    Molecular prediction of durable remission after first line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
    Blood. 2015 Aug 14. pii: blood-2015-05-647925.
    PubMed     Text format     Abstract available


  279. RICCIARDI MR, Mirabilii S, Allegretti M, Licchetta R, et al
    Targeting the leukemia cell metabolism by the CPT1a inhibition: functional pre-clinical effects in leukemias.
    Blood. 2015 Aug 14. pii: blood-2014-12-617498.
    PubMed     Text format     Abstract available


  280. PRATT D, Jaffe ES
    A window into cutaneous adult T-cell leukemia/lymphoma.
    Blood. 2015;126:920.
    PubMed     Text format    


  281. KAROL SE, Yang W, Van Driest SL, Chang TY, et al
    Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia.
    Blood. 2015 Aug 11. pii: blood-2015-05-643601.
    PubMed     Text format     Abstract available


  282. HRISINKO MA, Chen YH
    Rasburicase-induced Heinz body hemolytic anemia in a patient with chronic lymphocytic leukemia.
    Blood. 2015;126:826.
    PubMed     Text format    


  283. WANG W, Cortes JE, Lin P, Beaty MW, et al
    Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in chronic myelogenous leukemia in era of tyrosine kinase inhibitors.
    Blood. 2015 Aug 4. pii: blood-2015-05-646489.
    PubMed     Text format     Abstract available


    July 2015
  284. DAVIES DM, Maher J
    TSLPR: a new CAR in the showroom for B-ALL.
    Blood. 2015;126:567-9.
    PubMed     Text format    


  285. FORCONI F, Moss P
    Perturbation of the normal immune system in patients with CLL.
    Blood. 2015;126:573-81.
    PubMed     Text format     Abstract available


  286. QIN H, Cho M, Haso W, Zhang L, et al
    Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.
    Blood. 2015;126:629-39.
    PubMed     Text format     Abstract available


  287. ZHOU X, Zhou S, Li B, Li Q, et al
    Transmembrane TNF-alpha preferentially expressed by leukemia stem cells and blasts is a potent target for antibody therapy.
    Blood. 2015 Jul 29. pii: blood-2015-01-624833.
    PubMed     Text format     Abstract available


  288. SONG C, Gowda C, Pan X, Ding Y, et al
    Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.
    Blood. 2015 Jul 28. pii: blood-2015-06-651505.
    PubMed     Text format     Abstract available


  289. INABA H, Zhou Y, Abla O, Adachi S, et al
    Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study.
    Blood. 2015 Jul 27. pii: blood-2015-02-629204.
    PubMed     Text format     Abstract available


  290. ZHAO Q, Mahadeo KM, Kapoor N, Abdel-Azim H, et al
    Improved outcomes associated with hematopoietic stem cell transplantation for patients with juvenile myelomonocytic leukemia.
    Blood. 2015;126:561-2.
    PubMed     Text format    


  291. CHAN RY, Vergara-Lluri M
    Pseudoplatelets in acute myeloid leukemia.
    Blood. 2015;126:559.
    PubMed     Text format    


  292. LOGHAVI S, Khoury JD
    Disseminated blastic plasmacytoid dendritic cell neoplasm.
    Blood. 2015;126:558.
    PubMed     Text format    


  293. WOYACH JA, Johnson AJ
    Targeted therapies in CLL: mechanisms of resistance and strategies for management.
    Blood. 2015;126:471-7.
    PubMed     Text format     Abstract available


  294. STRATI P, Shanafelt TD
    Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification.
    Blood. 2015;126:454-62.
    PubMed     Text format     Abstract available


  295. JAIN N, O'Brien S
    Initial treatment of CLL: integrating biology and functional status.
    Blood. 2015;126:463-70.
    PubMed     Text format     Abstract available


  296. MATO A, Porter DL
    A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs.
    Blood. 2015;126:478-85.
    PubMed     Text format     Abstract available


  297. CHENG X, Byrne M, Brown KD, Konopleva MY, et al
    PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice.
    Blood. 2015 Jul 22. pii: blood-2015-03-635227.
    PubMed     Text format     Abstract available


  298. JACQUE N, Ronchetti AM, Larrue C, Meunier G, et al
    Targeting glutaminolysis has anti-leukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
    Blood. 2015 Jul 17. pii: blood-2015-01-621870.
    PubMed     Text format     Abstract available


  299. GRUBER TA, Downing JR
    The biology of pediatric acute megakaryoblastic leukemia.
    Blood. 2015 Jul 17. pii: blood-2015-05-567859.
    PubMed     Text format     Abstract available


  300. CHENG H, Hao S, Liu Y, Pang Y, et al
    Leukemic marrow infiltration reveals a novel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation.
    Blood. 2015 Jul 17. pii: blood-2015-01-623645.
    PubMed     Text format     Abstract available


  301. DANILOVA OV, Danilov AV
    Pericardial involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Blood. 2015;126:424.
    PubMed     Text format    


  302. HULS G
    Azacitidine in AML: a treatment option?
    Blood. 2015;126:283-4.
    PubMed     Text format     Abstract available


  303. IYER NS, Balsamo LM, Bracken MB, Kadan-Lottick NS, et al
    Chemotherapy-only treatment effects on long-term neurocognitive functioning in childhood ALL survivors: a review and meta-analysis.
    Blood. 2015;126:346-53.
    PubMed     Text format     Abstract available


  304. ARAI Y, Takeda J, Aoki K, Kondo T, et al
    Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.
    Blood. 2015;126:415-22.
    PubMed     Text format     Abstract available


  305. DOMBRET H, Seymour JF, Butrym A, Wierzbowska A, et al
    International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
    Blood. 2015;126:291-9.
    PubMed     Text format     Abstract available


  306. PANDOLFI A, Stanley RF, Yu Y, Bartholdy B, et al
    PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.
    Blood. 2015 Jul 13. pii: blood-2014-12-618801.
    PubMed     Text format     Abstract available


  307. LAFOURESSE F, Bellard E, Laurent C, Moussion C, et al
    L-selectin controls trafficking of chronic lymphocytic leukemia cells in lymph node high endothelial venules in vivo.
    Blood. 2015 Jul 10. pii: blood-2015-02-626291.
    PubMed     Text format     Abstract available


  308. JONEJA U, Uppal G
    Pseudo-Pelger-Huet anomaly in a patient on tacrolimus.
    Blood. 2015;126:277.
    PubMed     Text format    


  309. KATER AP, van der Windt GJ
    PD-L1 blockade: rejuvenating T cells in CLL.
    Blood. 2015;126:126-8.
    PubMed     Text format    


  310. MCCLANAHAN F, Riches JC, Miller S, Day WP, et al
    Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Emicro-TCL1 CLL mouse model.
    Blood. 2015;126:212-21.
    PubMed     Text format     Abstract available


  311. WU Y, Heinrichs J, Bastian D, Fu J, et al
    MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice.
    Blood. 2015 Jul 2. pii: blood-2015-02-627356.
    PubMed     Text format     Abstract available


  312. LUU HS, Rahaman PA
    Mature neutrophils with Auer rods following treatment with all-trans retinoic acid for acute promyelocytic leukemia.
    Blood. 2015;126:121.
    PubMed     Text format    


  313. FERNANDEZ CA, Smith C, Yang W, Mullighan CG, et al
    Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.
    Blood. 2015;126:69-75.
    PubMed     Text format     Abstract available


  314. LIU TM, Woyach JA, Zhong Y, Lozanski A, et al
    Hypermorphic mutation of phospholipase C, gamma2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
    Blood. 2015;126:61-8.
    PubMed     Text format     Abstract available


  315. WHITE DL, Hughes TP
    Living with CML: is death no longer the end (point)?
    Blood. 2015;126:2-4.
    PubMed     Text format    


    June 2015
  316. CIUREA SO, Zhang MJ, Bacigalupo AA, Bashey A, et al
    Haploidentical transplant with post-transplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia.
    Blood. 2015 Jun 30. pii: blood-2015-04-639831.
    PubMed     Text format     Abstract available


  317. MORADI MANESH D, El-Hoss J, Evans K, Richmond J, et al
    AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.
    Blood. 2015 Jun 26. pii: blood-2014-12-618900.
    PubMed     Text format     Abstract available


  318. JAGLOWSKI SM, Jones JA, Nagar V, Flynn JM, et al
    Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
    Blood. 2015 Jun 26. pii: blood-2014-12-617522.
    PubMed     Text format     Abstract available


  319. HUNGER SP, Mullighan CG
    Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine.
    Blood. 2015;125:3977-87.
    PubMed     Text format     Abstract available


  320. BLUNT MD, Carter MJ, Larrayoz M, Smith LD, et al
    The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Emicro-TCL1 mouse model.
    Blood. 2015;125:4032-41.
    PubMed     Text format     Abstract available


  321. PLUNKETT W
    Arginine addiction in AML.
    Blood. 2015;125:3971-2.
    PubMed     Text format     Abstract available


  322. PAGGETTI J, Haderk F, Seiffert M, Janji B, et al
    Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts.
    Blood. 2015 Jun 22. pii: blood-2014-12-618025.
    PubMed     Text format     Abstract available


  323. ARUCH DB, Renteria A
    Simultaneous PRES and TMA secondary to tacrolimus after allogeneic bone marrow transplant.
    Blood. 2015;125:3963.
    PubMed     Text format    


  324. FERNANDEZ HF
    Beyond the first glance: anthracyclines in AML.
    Blood. 2015;125:3828-9.
    PubMed     Text format    


  325. WANG Y, Liu QF, Xu LP, Liu KY, et al
    Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study.
    Blood. 2015;125:3956-62.
    PubMed     Text format     Abstract available


  326. BURNETT AK, Russell NH, Hills RK, Kell J, et al
    A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
    Blood. 2015;125:3878-85.
    PubMed     Text format     Abstract available


  327. ALEMDEHY MF, Haanstra JR, de Looper HW, van Strien PM, et al
    ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation.
    Blood. 2015;125:3937-48.
    PubMed     Text format     Abstract available


  328. WANG L, Man N, Sun XJ, Tan Y, et al
    Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression.
    Blood. 2015 Jun 17. pii: blood-2015-03-635532.
    PubMed     Text format     Abstract available


  329. BYRD JC
    Introduction to a Series of Reviews on Chronic lymphocytic leukemia (CLL).
    Blood. 2015 Jun 11. pii: blood-2015-06-639161.
    PubMed     Text format    


  330. GUIEZE R, Wu CJ
    Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia.
    Blood. 2015 Jun 11. pii: blood-2015-02-585042.
    PubMed     Text format     Abstract available


  331. KIM DY, Joo YD, Lim SN, Kim SD, et al
    Nilotinib combined with multi-agent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
    Blood. 2015 Jun 11. pii: blood-2015-03-636548.
    PubMed     Text format     Abstract available


  332. DIETRICH S, Hullein J, Lee SC, Hutter B, et al
    Recurrent CDKN1B (p27) mutations in hairy cell leukemia.
    Blood. 2015 Jun 11. pii: blood-2015-04-643361.
    PubMed     Text format     Abstract available


  333. WUILLEME S, Le Bris Y
    Misleading acute promyelocytic leukemia morphology.
    Blood. 2015;125:3815.
    PubMed     Text format    


  334. YANADA M
    Time to tune the treatment of Ph+ ALL.
    Blood. 2015;125:3674-5.
    PubMed     Text format     Abstract available


  335. WERMKE M, Camgoz A, Paszkowski-Rogacz M, Thieme S, et al
    RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug.
    Blood. 2015;125:3760-8.
    PubMed     Text format     Abstract available


  336. WADA T, Koyama D, Kikuchi J, Honda H, et al
    Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem cells for malignant transformation.
    Blood. 2015;125:3731-46.
    PubMed     Text format     Abstract available


  337. PAN R, Ruvolo VR, Wei J, Konopleva M, et al
    Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Blood. 2015 Jun 4. pii: blood-2014-10-604975.
    PubMed     Text format     Abstract available


  338. GATTINONI L
    The dark side of T memory stem cells.
    Blood. 2015;125:3519-20.
    PubMed     Text format    


  339. LI Y, Shi Y, McCaw L, Li YJ, et al
    Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A.
    Blood. 2015 Jun 3. pii: blood-2014-12-618678.
    PubMed     Text format     Abstract available


  340. CHO BS, Zeng Z, Mu H, Wang Z, et al
    Anti-leukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.
    Blood. 2015 Jun 1. pii: blood-2015-02-628677.
    PubMed     Text format     Abstract available


  341. RODRIGUEZ D, Bretones G, Quesada V, Villamor N, et al
    Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia.
    Blood. 2015 Jun 1. pii: blood-2014-10-604959.
    PubMed     Text format     Abstract available


    May 2015
  342. MORENO C
    Chronic lymphocytic leukemia and the Warburg effect.
    Blood. 2015;125:3368-9.
    PubMed     Text format    


  343. GRANT S
    ATRA and ATO team up against NPM1.
    Blood. 2015;125:3369-71.
    PubMed     Text format     Abstract available


  344. SIMPSON RJ
    Fitness deficits in long-term ALL survivors.
    Blood. 2015;125:3366-8.
    PubMed     Text format     Abstract available


  345. PULSIPHER MA, Carlson C, Langholz B, Wall DA, et al
    IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
    Blood. 2015;125:3501-8.
    PubMed     Text format     Abstract available


  346. EL HAJJ H, Dassouki Z, Berthier C, Raffoux E, et al
    Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells.
    Blood. 2015;125:3447-54.
    PubMed     Text format     Abstract available


  347. MARTELLI MP, Gionfriddo I, Mezzasoma F, Milano F, et al
    Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.
    Blood. 2015;125:3455-65.
    PubMed     Text format     Abstract available


  348. JITSCHIN R, Braun M, Qorraj M, Saul D, et al
    Stromal cell-mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling.
    Blood. 2015;125:3432-6.
    PubMed     Text format     Abstract available


  349. SOULIER J, Cortes J
    Introduction to the Review Series on Acute Lymphoblastic Leukemia.
    Blood. 2015 May 21. pii: blood-2015-05-635300.
    PubMed     Text format    


  350. JABBOUR E, O'Brien S, Ravandi F, Kantarjian H, et al
    Monoclonal antibodies in acute lymphoblastic leukemia.
    Blood. 2015 May 21. pii: blood-2014-08-596403.
    PubMed     Text format     Abstract available


  351. MAUDE SL, Teachey DT, Porter DL, Grupp SA, et al
    CD19-targeted chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia.
    Blood. 2015 May 21. pii: blood-2014-12-580068.
    PubMed     Text format     Abstract available


  352. MORIYAMA T, Relling MV, Yang JJ
    Inherited genetic variation in childhood acute lymphoblastic leukemia.
    Blood. 2015 May 21. pii: blood-2014-12-580001.
    PubMed     Text format     Abstract available


  353. VAN DONGEN JJ, van der Velden VH, Bruggemann M, Orfao A, et al
    Minimal residual disease (MRD) diagnostics in acute lymphoblastic leukemia (ALL): need for sensitive, fast and standardized technologies.
    Blood. 2015 May 21. pii: blood-2015-03-580027.
    PubMed     Text format     Abstract available


  354. GIRI S, Pathak R, Aryal MR, Karmacharya P, et al
    Impact of hospital volume on outcomes of patients undergoing chemotherapy for acute myeloid leukemia: a matched cohort study.
    Blood. 2015;125:3359-60.
    PubMed     Text format    


  355. OEVERMANN L, Firnkorn M, Michaelis S, Muller S, et al
    No association between the presence of killer-cell immunoglobulin-like receptor genes and susceptibility to childhood ALL.
    Blood. 2015;125:3355-7.
    PubMed     Text format    


  356. YEH YY, Ozer HG, Lehman AM, Maddocks K, et al
    Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.
    Blood. 2015;125:3297-305.
    PubMed     Text format     Abstract available


  357. SOMASUNDARAM R, Prasad M, Ungerback J, Sigvardsson M, et al
    Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia.
    Blood. 2015 May 19. pii: blood-2014-12-575688.
    PubMed     Text format     Abstract available


  358. SAUNTHARARAJAH Y
    Targets of opportunity for precision medicine.
    Blood. 2015;125:3041-2.
    PubMed     Text format    


  359. NONAMI A, Sattler M, Weisberg E, Liu Q, et al
    Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.
    Blood. 2015;125:3133-43.
    PubMed     Text format     Abstract available


  360. MANCUSI A, Ruggeri L, Urbani E, Pierini A, et al
    Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality.
    Blood. 2015;125:3173-82.
    PubMed     Text format     Abstract available


  361. FREY NV, Luger SM
    How I treat adults with relapsed or refractory Philadelphia chromosome negative acute lymphoblastic leukemia.
    Blood. 2015 May 12. pii: blood-2014-09-551937.
    PubMed     Text format     Abstract available


  362. LITZOW MR, Ferrando AA
    How we treat T-cell acute lymphoblastic leukemia in adults.
    Blood. 2015 May 12. pii: blood-2014-10-551895.
    PubMed     Text format     Abstract available


  363. LEE S, Mascarenhas JO
    Dysplastic changes of peripheral eosinophils in acute myeloid leukemia with myelodysplastic syndrome-related features.
    Blood. 2015;125:3032.
    PubMed     Text format    


  364. MUSCHEN M
    Ph+ ALL: drawing strength from a benign past.
    Blood. 2015;125:2879-80.
    PubMed     Text format     Abstract available


  365. WENDTNER CM, Fischer K
    Targeted drugs in concert with chemo: opposites attract.
    Blood. 2015;125:2878-9.
    PubMed     Text format     Abstract available


  366. CUI Y, Onozawa M, Garber HR, Samsel L, et al
    Thymic expression of a T-cell receptor targeting a tumor-associated antigen coexpressed in the thymus induces T-ALL.
    Blood. 2015;125:2958-67.
    PubMed     Text format     Abstract available


    April 2015
  367. RECHER C
    INPP4B, a new player in the chemoresistance of AML.
    Blood. 2015;125:2738-9.
    PubMed     Text format    


  368. SCHNELL SA, Ambesi-Impiombato A, Sanchez-Martin M, Belver L, et al
    Therapeutic targeting of HES1 transcriptional programs in T-ALL.
    Blood. 2015;125:2806-14.
    PubMed     Text format     Abstract available


  369. BROWN JR, O'Brien S, Kingsley CD, Eradat H, et al
    Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.
    Blood. 2015;125:2779-85.
    PubMed     Text format     Abstract available


  370. RIJAL S, Fleming S, Cummings N, Rynkiewicz NK, et al
    Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML.
    Blood. 2015;125:2815-24.
    PubMed     Text format     Abstract available


  371. CALVO KR, Price S, Braylan RC, Oliveira JB, et al
    JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities.
    Blood. 2015;125:2753-8.
    PubMed     Text format     Abstract available


  372. ZHAO M, Li L
    Osteoblast ablation burns out functional stem cells.
    Blood. 2015;125:2590-1.
    PubMed     Text format    



  373. SCT in high-risk Ph-negative adult ALL.
    Blood. 2015;125:2586.
    PubMed     Text format    


  374. FORCONI F
    Three years of ibrutinib in CLL.
    Blood. 2015;125:2455-6.
    PubMed     Text format     Abstract available


  375. LITZOW MR
    Finally moving forward in adult ALL.
    Blood. 2015;125:2453-4.
    PubMed     Text format     Abstract available


  376. BYRD JC, Furman RR, Coutre SE, Burger JA, et al
    Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
    Blood. 2015;125:2497-506.
    PubMed     Text format     Abstract available


  377. FUCHS EJ
    Haplo graft engineering: sculpting to a T.
    Blood. 2015;125:2315-6.
    PubMed     Text format     Abstract available


  378. MUSSAI F, Egan S, Higginbotham-Jones J, Perry T, et al
    Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.
    Blood. 2015;125:2386-96.
    PubMed     Text format     Abstract available


  379. AIROLDI I, Bertaina A, Prigione I, Zorzoli A, et al
    gammadelta T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-alphabeta+/CD19+ lymphocytes.
    Blood. 2015;125:2349-58.
    PubMed     Text format     Abstract available


  380. DE ROOIJ MF, Kuil A, Kater AP, Kersten MJ, et al
    Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
    Blood. 2015;125:2306-9.
    PubMed     Text format    


    March 2015
  381. PINILLA-IBARZ J, Chavez JC
    Life after ibrutinib? A new unmet need in CLL.
    Blood. 2015;125:2013-4.
    PubMed     Text format     Abstract available


  382. MANZONI D, Sujobert P
    Diagnosis of bacteremia on a blood smear.
    Blood. 2015;125:2173.
    PubMed     Text format    


  383. SRISKANTHADEVAN S, Jeyaraju DV, Chung TE, Prabha S, et al
    AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress.
    Blood. 2015;125:2120-30.
    PubMed     Text format     Abstract available


  384. SCHINKE C, Giricz O, Li W, Shastri A, et al
    IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
    Blood. 2015 Mar 25. pii: blood-2015-01-621631.
    PubMed     Text format     Abstract available


  385. OELLERICH T, Mohr S, Corso J, Beck J, et al
    FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation.
    Blood. 2015;125:1936-47.
    PubMed     Text format     Abstract available


  386. RASSOOL F, Perrotti D
    A "RANning" leap with "XPOrt" into TKI resistance.
    Blood. 2015;125:1686-8.
    PubMed     Text format    


  387. KHORASHAD JS, Eiring AM, Mason CC, Gantz KC, et al
    shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
    Blood. 2015;125:1772-81.
    PubMed     Text format     Abstract available


  388. GOYAMA S, Wunderlich M, Mulloy JC
    Xenograft models for normal and malignant stem cells.
    Blood. 2015 Mar 11. pii: blood-2014-11-570218.
    PubMed     Text format     Abstract available


  389. HERLING M, Vasyutina E
    Multilevel BCR signals toward CLL.
    Blood. 2015;125:1510-2.
    PubMed     Text format     Abstract available


    February 2015
  390. HANTSCHEL O
    Targeting BCR-ABL and JAK2 in Ph+ ALL.
    Blood. 2015;125:1362-3.
    PubMed     Text format     Abstract available


  391. WALTER MJ
    What came first: MDS or AML?
    Blood. 2015;125:1357-8.
    PubMed     Text format     Abstract available


  392. APPELMANN I, Rillahan CD, de Stanchina E, Carbonetti G, et al
    Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.
    Blood. 2015;125:1444-51.
    PubMed     Text format     Abstract available


    August 2014
  393. SO AY, Sookram R, Chaudhuri AA, Minisandram A, et al
    Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias.
    Blood. 2014;124:1502-12.
    PubMed     Text format     Abstract available


  394. DOHNER H, Lubbert M, Fiedler W, Fouillard L, et al
    Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.
    Blood. 2014;124:1426-33.
    PubMed     Text format     Abstract available


  395. EL-GAMAL D, Williams K, LaFollette TD, Cannon M, et al
    PKC-beta as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.
    Blood. 2014;124:1481-91.
    PubMed     Text format     Abstract available


  396. MALCOVATI L, Papaemmanuil E, Ambaglio I, Elena C, et al
    Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
    Blood. 2014;124:1513-21.
    PubMed     Text format     Abstract available


  397. RUMI E, Pietra D, Pascutto C, Guglielmelli P, et al
    Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
    Blood. 2014;124:1062-9.
    PubMed     Text format     Abstract available


  398. CONNELLY JP, Kwon EM, Gao Y, Trivedi NS, et al
    Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects.
    Blood. 2014 Aug 11. pii: blood-2014-01-550525.
    PubMed     Text format     Abstract available


    June 2014
  399. GALLIPOLI P, Cook A, Rhodes S, Hopcroft L, et al
    JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD34+ cells in vitro and in vivo.
    Blood. 2014 Jun 23. pii: blood-2013-12-545640.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: